Strides Pharma Science Ltd - 532531 - Voting Results Of Postal Ballot Pursuant To Regulation 44 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 And Scrutinizer'S Report.
Voting Results of Postal Ballot pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Scrutinizer's Report. Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for Loss of Share Certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for Loss of Share Certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Accumulate Strides Pharma Science; target of Rs 355: Geojit
Geojit recommended accumulate rating on Strides Pharma Science with a target price of Rs 355 in its research report dated June 23, 2022. Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding request received for Loss of Share Certificate under Regulation 39 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Stelis Biopharma's two biologics manufacturing facilities receive EU cGMP accreditation Strides Pharma Science Ltd - 532531 - Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on June 13, 2022 for Arun Kumar Pillai
IPL Media Rights auction: STAR India wins TV, Viacom18 bags digital rights, confirms Jay Shah
Shah mentioned that the Indian Premier League (IPL) is now the second- most valued sporting league in the world in terms of per match value. Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 13, 2022 for Pronomz Ventures LLP & Arun Kumar